Bionano net loss widens 8.26% to $7.42 million in Q2 FY26; revenue rises 21% to $8.2 million

Reuters2026/08/10 20:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bionano Genomics reported Q2 revenue of USD 8.2 million, up 21% year over year, as consumables rose 31% to USD 4.3 million.
Net loss widened to USD 7.42 million, while gross margin edged up 1 percentage point to 53%.
Flow-cell volume climbed 27% to 9,219, while operating expenses increased 2% to USD 11.5 million.
Management cited accelerating global adoption of optical genome mapping, driven mainly by increased clinical adoption and higher utilization at clinical sites.
Issued Q3 revenue guidance of USD 8.2 million-USD 8.6 million, maintaining full-year guidance of USD 31 million-USD 33 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionano Genomics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101605PRIMZONEFULLFEED9807037) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bionano net loss widens 8.26% to $7.42 million in Q2 FY26; revenue rises 21% to $8.2 million

You may also like

Crypto prices